Tissue Regenix Group Statistics
Total Valuation
Tissue Regenix Group has a market cap or net worth of GBP 42.38 million. The enterprise value is 47.38 million.
Market Cap | 42.38M |
Enterprise Value | 47.38M |
Important Dates
The last earnings date was Tuesday, September 10, 2024.
Earnings Date | Sep 10, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Tissue Regenix Group has 71.23 million shares outstanding. The number of shares has increased by 0.08% in one year.
Shares Outstanding | 71.23M |
Shares Change (YoY) | +0.08% |
Shares Change (QoQ) | +0.20% |
Owned by Insiders (%) | 24.60% |
Owned by Institutions (%) | 46.60% |
Float | 45.83M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 1.66 |
PB Ratio | 1.76 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 43.39, with an EV/FCF ratio of -604.85.
EV / Earnings | -54.39 |
EV / Sales | 1.88 |
EV / EBITDA | 43.39 |
EV / EBIT | 164.96 |
EV / FCF | -604.85 |
Financial Position
The company has a current ratio of 3.74, with a Debt / Equity ratio of 35.69.
Current Ratio | 3.74 |
Quick Ratio | 1.47 |
Debt / Equity | 35.69 |
Debt / EBITDA | 7.59 |
Debt / FCF | -105.78 |
Interest Coverage | 0.49 |
Financial Efficiency
Return on equity (ROE) is -3.31% and return on invested capital (ROIC) is 0.57%.
Return on Equity (ROE) | -3.31% |
Return on Assets (ROA) | 0.50% |
Return on Capital (ROIC) | 0.57% |
Revenue Per Employee | 306,829 |
Profits Per Employee | -10,624 |
Employee Count | 82 |
Asset Turnover | 0.71 |
Inventory Turnover | 1.33 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +10.19% in the last 52 weeks.
Beta (5Y) | n/a |
52-Week Price Change | +10.19% |
50-Day Moving Average | 65.32 |
200-Day Moving Average | 62.25 |
Relative Strength Index (RSI) | 25.50 |
Average Volume (20 Days) | 29,958 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Tissue Regenix Group had revenue of GBP 25.16 million and -871,188 in losses. Loss per share was -0.01.
Revenue | 25.16M |
Gross Profit | 12.45M |
Operating Income | 287,231 |
Pretax Income | -485,840 |
Net Income | -871,188 |
EBITDA | 981,966 |
EBIT | 287,231 |
Loss Per Share | -0.01 |
Balance Sheet
The company has 2.74 million in cash and 8.29 million in debt, giving a net cash position of -5.55 million or -0.08 per share.
Cash & Cash Equivalents | 2.74M |
Total Debt | 8.29M |
Net Cash | -5.55M |
Net Cash Per Share | -0.08 |
Equity (Book Value) | 23.22M |
Book Value Per Share | 0.34 |
Working Capital | 12.14M |
Cash Flow
In the last 12 months, operating cash flow was 283,275 and capital expenditures -361,610, giving a free cash flow of -78,335.
Operating Cash Flow | 283,275 |
Capital Expenditures | -361,610 |
Free Cash Flow | -78,335 |
FCF Per Share | -0.00 |
Margins
Gross margin is 49.48%, with operating and profit margins of 1.14% and -3.46%.
Gross Margin | 49.48% |
Operating Margin | 1.14% |
Pretax Margin | -1.93% |
Profit Margin | -3.46% |
EBITDA Margin | 3.90% |
EBIT Margin | 1.14% |
FCF Margin | -0.31% |
Dividends & Yields
Tissue Regenix Group does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -0.08% |
Shareholder Yield | -0.08% |
Earnings Yield | -2.08% |
FCF Yield | -0.18% |
Stock Splits
The last stock split was on April 28, 2023. It was a reverse split with a ratio of 0.01.
Last Split Date | Apr 28, 2023 |
Split Type | Reverse |
Split Ratio | 0.01 |